Skip to content

BioNexus Gene Lab Corp.

BGLC

CIK 0001737523

← back to feed
Revenue (TTM)
$6.96M
−21.9% YoY Q1 May 2026
Net Income (TTM)
−$2.49M
−86.7% YoY Q1 May 2026
EPS Diluted (TTM)
−$1.31
+45.8% YoY Q1 May 2026
Gross Margin
15.6%
Q1 May 2026
Operating Margin
-35.5%
Q1 May 2026
Net Margin
-35.8%
Q1 May 2026
Free Cash Flow (TTM)
−$1.16M
Q1 May 2026
Cash
$2.49M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
2.42M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings